The patient developed Severe-IRIS-KS after valganciclovir discontinuation when HHV-8 VL rebounded and CD4+ cells increased, and when he resumed treatment, HHV-8 VL decreased and the Severe-IRIS-KS episode ceased, achieving 90% remission at week-48. This evidence concerns the gene CD4 and Kaposi's sarcoma.